Directory
>
Jim Watters
Jim Watters
Chief Scientific Officer | Relay Therapeutics
Cambridge, Massachusetts, United States
Jim Watters
Summary
Jim Watters is a seasoned leader in drug discovery, currently serving as the Chief Scientific Officer at Relay Therapeutics, where he focuses on integrating scientific innovation with technology to advance precision medicine. With a robust background in biochemistry and molecular biology, he has a proven track record in oncology and rare genetic diseases. His experience spans over two decades, including significant roles at Sanofi and Merck, where he led global teams in translational and experimental medicine. Jim's academic credentials include a PhD in Genetics from Harvard University and a BS in Biology from Purdue University. He is passionate about leveraging biomarker discovery to enhance clinical outcomes and is committed to mentoring the next generation of scientists. Outside of his professional endeavors, he enjoys exploring the intersection of science and technology, reflecting a deep curiosity about emerging trends in the life sciences.
Jim Watters
Work Experience
Chief Scientific Officer at
Relay Therapeutics
September 2024 - Present
Chief Scientific Officer, Late Research at
Relay Therapeutics
January 2022 - September 2024
Senior Vice President, Head of Late Research at
Relay Therapeutics
November 2020 - January 2022
Senior Vice President, Biology at
Relay Therapeutics
March 2016 - November 2020
Strategic Advisor at
Third Rock Ventures
September 2015 - March 2016
Global Head, Translational and Experimental Medicine at
Sanofi
May 2014 - September 2015
Senior Director, Translational and Experimental Medicine at
Sanofi
May 2013 - April 2014
Director, Applied Genomics at
Sanofi
September 2010 - May 2013
Associate Director at
Merck
January 2005 - September 2010
Postdoctoral Fellow at
Washington University In St Louis
November 2001 - January 2005
Jim Watters
Education
Harvard University, Phd
January 1996 - January 2001
January 1992 - January 1996
Frequently Asked Questions about Jim Watters
What is Jim Watters email address?
Jim Watters's primary email address is ********@relaytx.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Jim Watters work for?
Jim Watters is a Chief Scientific Officer at Relay Therapeutics, a company specializing in Commercial physical research.
Where Jim Watters graduated from?
Jim Watters holds a degree in Genetics from Harvard University.
How can I directly contact Jim Watters?
To contact Jim Watters directly, you can use the email address ********@relaytx.com. Complete contact information is available upon registration with Muraena.
Who is Jim Watters?
Jim Watters is a seasoned leader in drug discovery, currently serving as the Chief Scientific Officer at Relay Therapeutics, where he focuses on integrating scientific innovation with technology to advance precision medicine. With a robust background in biochemistry and molecular biology, he has a proven track record in oncology and rare genetic diseases. His experience spans over two decades, including significant roles at Sanofi and Merck, where he led global teams in translational and experimental medicine. Jim's academic credentials include a PhD in Genetics from Harvard University and a BS in Biology from Purdue University. He is passionate about leveraging biomarker discovery to enhance clinical outcomes and is committed to mentoring the next generation of scientists. Outside of his professional endeavors, he enjoys exploring the intersection of science and technology, reflecting a deep curiosity about emerging trends in the life sciences.
Jim`s contact details
********@relaytx.com
Colleagues
Vice President Patient Safety Risk Management
Chief Corporate Development Officer
Chief Medical Officer
Senior Vice President, Head of Clinical Development
Vice President - Computational Chemistry
Vice President, Drug Substance Development and Manufacturing (CMC)
Vice President, R&D Portfolio Strategy & Operations
President & CEO
Vice President, Investor Relations & Communications
VP Clinical Science